The BioPharm Brief: Breakthroughs, Bispecifics, and Biosimilars

Jun 04, 05:42 PM
Headliner
Share
Subscribe

Today's biopharmaceutical news highlights an FDA breakthrough designation in spinal muscular atrophy, an expanded oncology collaboration focused on tumor activated bispecifics, and a new biosimilar launch for retinal diseases in Europe.

Share
Subscribe
Next
The BioPharm Brief: RNA Editing, Cardiac Remodeling, Rare Disease Gene Therapy
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief